| scholarly article | Q13442814 |
| P50 | author | John W. Huffman | Q651534 |
| Zoltan Ungvari | Q60324829 | ||
| Pal Pacher | Q30347235 | ||
| Partha Mukhopadhyay | Q37379024 | ||
| Ken Mackie | Q37831452 | ||
| P2093 | author name string | György Haskó | |
| Lucas Liaudet | |||
| Mohanraj Rajesh | |||
| Anna Csiszar | |||
| Sándor Bátkai | |||
| Subroto Chatterjee | |||
| P2860 | cites work | Nitric oxide and peroxynitrite in health and disease | Q24645400 |
| The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 | ||
| Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity | Q24648835 | ||
| Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease | Q28273656 | ||
| Identification and functional characterization of brainstem cannabinoid CB2 receptors | Q28276972 | ||
| HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor | Q28343769 | ||
| 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor | Q28369726 | ||
| Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats | Q46395817 | ||
| Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice | Q46432117 | ||
| Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis | Q46434986 | ||
| Inhibition of nuclear factor-kappaB attenuates artherosclerosis in apoE/LDLR - double knockout mice. | Q46735818 | ||
| Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production | Q46917530 | ||
| Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase | Q47425860 | ||
| Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. | Q51531918 | ||
| Inhibition of tumor angiogenesis by cannabinoids | Q56638578 | ||
| Roles of Glycosphingolipids in Cell Signaling: Adhesion, Migration, and Proliferation | Q57363620 | ||
| C-Reactive Protein, Interleukin-6, and Soluble Adhesion Molecules as Predictors of Progressive Peripheral Atherosclerosis in the General Population | Q57403312 | ||
| ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells | Q64378699 | ||
| Lactosylceramide mediates tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells | Q64381769 | ||
| Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells | Q71682090 | ||
| Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro | Q72187792 | ||
| Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells | Q74256790 | ||
| Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN | Q79346672 | ||
| A functional role of I kappa B-epsilon in endothelial cell activation | Q33892613 | ||
| Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells | Q33905168 | ||
| Cell signaling by reactive nitrogen and oxygen species in atherosclerosis | Q34006311 | ||
| Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | Q34179008 | ||
| Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. | Q34409573 | ||
| Cannabinoid receptors as therapeutic targets. | Q34482964 | ||
| Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes | Q34497846 | ||
| Cytokines in atherosclerosis: pathogenic and regulatory pathways | Q34511711 | ||
| Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis | Q34655802 | ||
| Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype | Q35087897 | ||
| Role of oxidative stress in atherosclerosis | Q35088521 | ||
| Role of Monocytes in Atherogenesis | Q35541858 | ||
| Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway | Q35652010 | ||
| Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. | Q35912206 | ||
| RHO SIGNALING in vascular diseases | Q35992317 | ||
| Cannabinoid-based drugs as anti-inflammatory therapeutics | Q36111923 | ||
| Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury | Q36431793 | ||
| The immune response in atherosclerosis: a double-edged sword | Q36508676 | ||
| Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model | Q37087780 | ||
| Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation | Q37926154 | ||
| Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells | Q40612911 | ||
| Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells | Q40771063 | ||
| Mechanisms of neutrophil-induced parenchymal cell injury | Q41513491 | ||
| Cellular adhesion molecules: regulation and functional significance in the pathogenesis of liver diseases | Q41619005 | ||
| Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. | Q43887376 | ||
| Tumor Necrosis Factor-α Induces Early-Onset Endothelial Adhesivity by Protein Kinase Cζ–Dependent Activation of Intercellular Adhesion Molecule-1 | Q44417182 | ||
| Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice | Q45042448 | ||
| Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors | Q45153412 | ||
| The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection | Q45413276 | ||
| P433 | issue | 4 | |
| P921 | main subject | endothelium | Q111140 |
| cell migration | Q189092 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | H2210-8 | |
| P577 | publication date | 2007-07-27 | |
| P1433 | published in | American Journal of Physiology Heart and Circulatory Physiology | Q3193662 |
| P1476 | title | CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion | |
| P478 | volume | 293 |
| Q35027428 | "Venopathy" at work: recasting neointimal hyperplasia in a new light |
| Q24615787 | A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss |
| Q64104446 | AM-1241 CB2 Receptor Agonist Attenuates Inflammation, Apoptosis and Stimulate Progenitor Cells in Bile Duct Ligated Rats |
| Q37300512 | Acetaminophen Use for Fever in Children Associated with Autism Spectrum Disorder |
| Q35887816 | Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions |
| Q39431492 | An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol |
| Q43190361 | Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action? |
| Q37637761 | Anti-inflammatory effects of cannabinoid CB(2) receptor activation in endotoxin-induced uveitis. |
| Q52615780 | Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. |
| Q34992040 | CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages |
| Q37160279 | CB1 cannabinoid receptor inhibition: promising approach for heart failure? |
| Q34098258 | CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model |
| Q34733645 | CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways |
| Q33745557 | CB2 receptor activation ameliorates the proinflammatory activity in acute lung injury induced by paraquat |
| Q35870490 | CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. |
| Q47202996 | Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation |
| Q34898890 | Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress |
| Q35966006 | Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation |
| Q34851941 | Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death |
| Q35766956 | Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy |
| Q35789673 | Cannabinoid 2 receptor activation reduces leukocyte adhesion and improves capillary perfusion in the iridial microvasculature during systemic inflammation. |
| Q43145354 | Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? |
| Q37253331 | Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. |
| Q36089227 | Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice |
| Q42110787 | Cannabinoid receptor 2 activation reduces intestinal leukocyte recruitment and systemic inflammatory mediator release in acute experimental sepsis |
| Q33889311 | Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice |
| Q38087533 | Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation |
| Q37174735 | Cannabinoid receptor CB2 protects against balloon-induced neointima formation |
| Q42206762 | Cannabinoid receptor-2 and HIV-associated neurocognitive disorders. |
| Q36416368 | Cannabinoid receptors in acute and chronic complications of atherosclerosis. |
| Q34098271 | Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells |
| Q33847549 | Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy |
| Q42653925 | Cannabinoid-like anti-inflammatory compounds from flax fiber. |
| Q39784439 | Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. |
| Q37978806 | Cannabinoids and atherosclerotic coronary heart disease |
| Q93343782 | Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle |
| Q37396781 | Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction |
| Q37149113 | Cannabinoids, endocannabinoids, and related analogs in inflammation |
| Q35560897 | Citreoviridin Enhances Atherogenesis in Hypercholesterolemic ApoE-Deficient Mice via Upregulating Inflammation and Endothelial Dysfunction |
| Q58777570 | Connexin 43 Hemichannel Activity Promoted by Pro-Inflammatory Cytokines and High Glucose Alters Endothelial Cell Function |
| Q38832242 | Cyclooxygenase metabolism mediates vasorelaxation to 2-arachidonoylglycerol (2-AG) in human mesenteric arteries. |
| Q36558056 | Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists |
| Q37768965 | Do cannabinoids have a therapeutic role in transplantation? |
| Q38468985 | Downstream effects of endocannabinoid on blood cells: implications for health and disease. |
| Q79819090 | Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users |
| Q94547350 | Effect of flaxseed oil supplementation on the erythrocyte membrane fatty acid composition and endocannabinoid system modulation in patients with coronary artery disease: a double-blind randomized controlled trial |
| Q35115683 | Effect of melilotus extract on lung injury by upregulating the expression of cannabinoid CB2 receptors in septic rats |
| Q38522557 | Effects of cannabinoids and their receptors on viral infections. |
| Q37794776 | Eicosanoid regulation of hematopoiesis and hematopoietic stem and progenitor trafficking |
| Q30300333 | Emerging therapeutic targets of sepsis-associated acute kidney injury |
| Q39411024 | Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations. |
| Q92188874 | Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease |
| Q38135915 | Endocannabinoid system as a potential mechanism for n-3 long-chain polyunsaturated fatty acid mediated cardiovascular protection |
| Q36416372 | Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning |
| Q37401757 | Endocannabinoids and cardiac contractile function: pathophysiological implications |
| Q36647969 | Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases |
| Q38593133 | Endocannabinoids and the Cardiovascular System in Health and Disease |
| Q37894978 | Endocannabinoids and the cardiovascular response to stress. |
| Q37412217 | Endocannabinoids and the heart. |
| Q36895795 | Endocannabinoids in cerebrovascular regulation |
| Q38931168 | Endocannabinoids in the gastrointestinal tract |
| Q40533421 | Endothelial Cell Activation Is Regulated by Epidermal Growth Factor-like Domain 7 (Egfl7) during Inflammation. |
| Q91576396 | Exogenous activation of cannabinoid-2 receptor modulates TLR4/MMP9 expression in a spinal cord ischemia reperfusion rat model |
| Q38923749 | Experimental cannabinoid 2 receptor-mediated immune modulation in sepsis |
| Q37067454 | Expression of the endocannabinoid receptors in human fascial tissue |
| Q38220272 | Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier |
| Q34993393 | HIV-1 infection and alcohol abuse: neurocognitive impairment, mechanisms of neurodegeneration and therapeutic interventions. |
| Q37697482 | HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation |
| Q28585150 | Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload |
| Q33645711 | Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro |
| Q93007899 | Interplay of Liver-Heart Inflammatory Axis and Cannabinoid 2 Receptor Signaling in an Experimental Model of Hepatic Cardiomyopathy |
| Q100395381 | Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications |
| Q24633122 | Is lipid signaling through cannabinoid 2 receptors part of a protective system? |
| Q60917775 | L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer |
| Q34179571 | Mechanisms of vascular aging: new perspectives. |
| Q91677632 | Mice Missing Cnr1 and Cnr2 Show Implantation Defects |
| Q36933683 | Modulating the endocannabinoid system in human health and disease--successes and failures |
| Q90322108 | Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues |
| Q36940347 | Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations |
| Q38684679 | Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation |
| Q34422088 | Palmitoylethanolamide regulates development of intestinal radiation injury in a mast cell-dependent manner |
| Q35693212 | Pathogenesis of Systemic Sclerosis |
| Q34155467 | Peroxisomal and microsomal lipid pathways associated with resistance to hepatic steatosis and reduced pro-inflammatory state |
| Q36496316 | Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases |
| Q37226537 | Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). |
| Q35179985 | Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy |
| Q48573535 | Response to Letter to the editor from Dr. Dale Ding: Abrogation of cerebral edema and vascular inflammation following subarachnoid hemorrhage by cannabinoid receptor activation. |
| Q36753588 | Rimonabant in rats with a metabolic syndrome: good news after the depression. |
| Q37271987 | Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier |
| Q36370835 | Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression |
| Q36346915 | Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies |
| Q90529594 | Targeting of G-protein coupled receptors in sepsis |
| Q33947213 | Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis |
| Q43493711 | Tetramethylpyrazine attenuates atherosclerosis development and protects endothelial cells from ox-LDL. |
| Q28066700 | The CB2 receptor and its role as a regulator of inflammation |
| Q50142905 | The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2. |
| Q38759802 | The cannabinoid 2 receptor agonist β-caryophyllene modulates the inflammatory reaction induced by Mycobacterium bovis BCG by inhibiting neutrophil migration. |
| Q28579415 | The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats |
| Q38455748 | The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe? |
| Q37439386 | The emerging role of the endocannabinoid system in cardiovascular disease |
| Q35951992 | The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications |
| Q46204521 | The endocannabinoid system in cardiovascular function: novel insights and clinical implications |
| Q28236199 | The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells |
| Q34919524 | The hexosamine biosynthesis inhibitor azaserine prevents endothelial inflammation and dysfunction under hyperglycemic condition through antioxidant effects |
| Q41821312 | The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets |
| Q42904836 | Translating Endocannabinoid Biology into Clinical Practice: Cannabidiol for Stroke Prevention |
| Q37330515 | Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. |
| Q86924782 | Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke |
| Q38068594 | Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology |
| Q26862515 | Vascular targets for cannabinoids: animal and human studies |
| Q35854652 | β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner |
Search more.